-
1
-
-
84873540049
-
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
-
COI: 1:CAS:528:DC%2BC3sXjslagtQ%3D%3D, PID: 23291630
-
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.
-
(2013)
Nat Med.
, vol.19
, Issue.2
, pp. 202-208
-
-
Souers, A.J.1
Leverson, J.D.2
Boghaert, E.R.3
Ackler, S.L.4
Catron, N.D.5
Chen, J.6
-
3
-
-
0242351062
-
The Bcl-2-regulated apoptotic pathway
-
COI: 1:CAS:528:DC%2BD3sXovFWmsL0%3D, PID: 12972498
-
Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003;116(Pt 20):4053–6.
-
(2003)
J Cell Sci.
, vol.116
, pp. 4053-4056
-
-
Willis, S.1
Day, C.L.2
Hinds, M.G.3
Huang, D.C.4
-
4
-
-
0037148840
-
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes
-
COI: 1:CAS:528:DC%2BD38Xhs12jt7w%3D, PID: 11859372
-
Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415(6874):922–6.
-
(2002)
Nature.
, vol.415
, Issue.6874
, pp. 922-926
-
-
Bouillet, P.1
Purton, J.F.2
Godfrey, D.I.3
Zhang, L.C.4
Coultas, L.5
Puthalakath, H.6
-
5
-
-
0037213368
-
The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions
-
COI: 1:CAS:528:DC%2BD38XpsV2qsr4%3D, PID: 12493639
-
Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39(11):615–47.
-
(2003)
Mol Immunol.
, vol.39
, Issue.11
, pp. 615-647
-
-
Borner, C.1
-
6
-
-
0142117313
-
The Bcl-2 family: roles in cell survival and oncogenesis
-
COI: 1:CAS:528:DC%2BD3sXptFOmtb0%3D, PID: 14634621
-
Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–607.
-
(2003)
Oncogene.
, vol.22
, Issue.53
, pp. 8590-8607
-
-
Cory, S.1
Huang, D.C.2
Adams, J.M.3
-
7
-
-
84955491187
-
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC28XhtV2murrP, PID: 26639348
-
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.
-
(2016)
N Engl J Med.
, vol.374
, Issue.4
, pp. 311-322
-
-
Roberts, A.W.1
Davids, M.S.2
Pagel, J.M.3
Kahl, B.S.4
Puvvada, S.D.5
Gerecitano, J.F.6
-
8
-
-
84997558826
-
A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma
-
Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254.
-
(2015)
Blood.
, vol.126
, Issue.23
, pp. 254
-
-
Gerecitano, J.F.1
Roberts, A.W.2
Seymour, J.F.3
Wierda, W.G.4
Kahl, B.S.5
Pagel, J.M.6
-
9
-
-
84990216612
-
Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results
-
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2015;126(23):3038.
-
(2015)
Blood.
, vol.126
, Issue.23
, pp. 3038
-
-
Moreau, P.1
Chanan-Khan, A.2
Roberts, A.W.3
Agarwal, A.B.4
Facon, T.5
Kumar, S.6
-
10
-
-
84990221683
-
A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy
-
DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126(23):327.
-
(2015)
Blood.
, vol.126
, Issue.23
, pp. 327
-
-
DiNardo, C.1
Pollyea, D.2
Pratz, K.3
Thirman, M.J.4
Letai, A.5
Frattini, M.6
-
11
-
-
85000652245
-
Deep and durable responses following venetoclax (ABT-199 / GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study
-
Ma S, Brander DM, Seymour JF, Kipps TJ, Barrientos JC, Davids MS, et al. Deep and durable responses following venetoclax (ABT-199 / GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126(23):494.
-
(2015)
Blood.
, vol.126
, Issue.23
, pp. 494
-
-
Ma, S.1
Brander, D.M.2
Seymour, J.F.3
Kipps, T.J.4
Barrientos, J.C.5
Davids, M.S.6
-
12
-
-
84970032000
-
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
-
COI: 1:CAS:528:DC%2BC28XnslGqsbc%3D, PID: 27178240
-
Stilgenbauer S, Eichhorst Barbara, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.
-
(2016)
Lancet Oncol.
, vol.17
, Issue.6
, pp. 768-778
-
-
Stilgenbauer, S.1
Eichhorst, B.2
Schetelig, J.3
Coutre, S.4
Seymour, J.F.5
Munir, T.6
-
13
-
-
84994106763
-
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
-
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al.
-
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. doi:10.1158/2159-8290.cd-16-0313. (Epub 12 Aug 2016).
-
Cancer Discov
-
-
-
14
-
-
84925263674
-
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
-
PID: 25787766
-
Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40.
-
(2015)
Sci Transl Med.
, vol.7
, Issue.279
, pp. 279ra40
-
-
Leverson, J.D.1
Phillips, D.C.2
Mitten, M.J.3
Boghaert, E.R.4
Diaz, D.5
Tahir, S.K.6
-
15
-
-
84975769164
-
Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
-
PID: 26516589
-
Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect. 2015;3(5):e00178.
-
(2015)
Pharmacol Res Perspect.
, vol.3
, Issue.5
-
-
Ackler, S.1
Oleksijew, A.2
Chen, J.3
Chyla, B.J.4
Clarin, J.5
Foster, K.6
-
16
-
-
80053032460
-
Choosing first-line therapy for chronic lymphocytic leukemia
-
PID: 21929312
-
Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011;11(9):1379–90.
-
(2011)
Expert Rev Anticancer Ther.
, vol.11
, Issue.9
, pp. 1379-1390
-
-
Jaglowski, S.1
Jones, J.A.2
-
17
-
-
33747892619
-
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BD28XpvVCrtb8%3D, PID: 16862572
-
Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023–33.
-
(2006)
Cancer.
, vol.107
, Issue.5
, pp. 1023-1033
-
-
Francis, S.1
Karanth, M.2
Pratt, G.3
Starczynski, J.4
Hooper, L.5
Fegan, C.6
-
18
-
-
0034727833
-
Genomic aberrations and survival in chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BD3MXktlSlsQ%3D%3D, PID: 11136261
-
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.
-
(2000)
N Engl J Med.
, vol.343
, Issue.26
, pp. 1910-1916
-
-
Dohner, H.1
Stilgenbauer, S.2
Benner, A.3
Leupolt, E.4
Krober, A.5
Bullinger, L.6
-
19
-
-
0031467237
-
In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients
-
COI: 1:STN:280:DyaK1c7gsFKkug%3D%3D, PID: 9444933
-
Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res. 1997;21(11–12):1011–23.
-
(1997)
Leuk Res.
, vol.21
, Issue.11-12
, pp. 1011-1023
-
-
Geisler, C.H.1
Philip, P.2
Christensen, B.E.3
Hou-Jensen, K.4
Pedersen, N.T.5
Jensen, O.M.6
-
20
-
-
79954999804
-
Understanding and managing ultra high-risk chronic lymphocytic leukemia
-
Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2010;2010:481–8.
-
(2010)
Hematol Am Soc Hematol Educ Program.
, vol.2010
, pp. 481-488
-
-
Stilgenbauer, S.1
Zenz, T.2
-
21
-
-
33644847307
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
-
COI: 1:CAS:528:DC%2BD28XhsFSku7g%3D, PID: 16344317
-
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437–43.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.3
, pp. 437-443
-
-
Byrd, J.C.1
Gribben, J.G.2
Peterson, B.L.3
Grever, M.R.4
Lozanski, G.5
Lucas, D.M.6
-
22
-
-
84970971332
-
Clinical predictors of venetoclax pharmacokinetics, a selective BCL-2 inhibitor, in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis
-
COI: 1:CAS:528:DC%2BC28XovFWhsLo%3D, PID: 27233802
-
Jones AK, Freise KJ, Agarwal S, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics, a selective BCL-2 inhibitor, in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192–202.
-
(2016)
AAPS J.
, vol.18
, Issue.5
, pp. 1192-1202
-
-
Jones, A.K.1
Freise, K.J.2
Agarwal, S.3
Humerickhouse, R.A.4
Wong, S.L.5
Salem, A.H.6
-
23
-
-
85016913192
-
September 25–27, North Bethesda
-
Jones AK, Freise KJ, Agarwal S, Verdugo M, Humerickhouse RA, Wong SL, Salem AH. Venetoclax pharmacokinetics in hematological malignancies subjects with renal and hepatic impairment. American College of Clinical Pharmacology Annual Meeting. 2016. September 25–27, North Bethesda, MD.
-
(2016)
-
-
-
24
-
-
84990250477
-
Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 Inhibitor
-
Agarwal SK, Hu B, Chien D, Wong SL, Salem AH.results of a single- and multiple-dose study.
-
Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 Inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. doi:10.1002/jcph.730. (Epub 7 Mar 2016).
-
J Clin Pharmacol
-
-
-
25
-
-
84990249282
-
-
Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor.
-
Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor. J Clin Pharmacol. doi:10.1002/jcph.741. (Epub 31 Mar 2016).
-
J Clin Pharmacol
-
-
-
26
-
-
85002931885
-
-
Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin’s lymphoma
-
Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin’s lymphoma. J Clin Pharmacol. doi:10.1002/jcph.821. (Epub 25 Aug 2016).
-
J Clin Pharmacol
-
-
-
27
-
-
84990192811
-
Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy
-
Jones J, Mato AR, Coutre S, Wierda W, Choi MY, Davids MS, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. Blood. 2015;126(23):715.
-
(2015)
Blood.
, vol.126
, Issue.23
, pp. 715
-
-
Jones, J.1
Mato, A.R.2
Coutre, S.3
Wierda, W.4
Choi, M.Y.5
Davids, M.S.6
-
28
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
-
COI: 1:CAS:528:DC%2BD1cXnsVOktrk%3D, PID: 18216293
-
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.
-
(2008)
Blood.
, vol.111
, Issue.12
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
Caligaris-Cappio, F.4
Dighiero, G.5
Dohner, H.6
-
29
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
PID: 17242396
-
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.5
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
Gascoyne, R.D.4
Specht, L.5
Horning, S.J.6
-
30
-
-
85046914570
-
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis
-
PID: 12645999
-
Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4(4):E27.
-
(2002)
AAPS PharmSci.
, vol.4
, Issue.4
, pp. E27
-
-
Wahlby, U.1
Jonsson, E.N.2
Karlsson, M.O.3
-
31
-
-
57749113071
-
In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow
-
PID: 19074880
-
van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JA, Vrisekoop N, et al. In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res. 2008;68(24):10137–44.
-
(2008)
Cancer Res.
, vol.68
, Issue.24
, pp. 10137-10144
-
-
van Gent, R.1
Kater, A.P.2
Otto, S.A.3
Jaspers, A.4
Borghans, J.A.5
Vrisekoop, N.6
-
33
-
-
84938596484
-
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
-
PID: 25957396
-
Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–6.
-
(2015)
Haematologica.
, vol.100
, Issue.8
, pp. e302-e306
-
-
Thijssen, R.1
Slinger, E.2
Weller, K.3
Geest, C.R.4
Beaumont, T.5
van Oers, M.H.6
-
34
-
-
84880261829
-
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition
-
COI: 1:CAS:528:DC%2BC3sXhtFWlu7%2FJ, PID: 23614795
-
Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54(8):1823–5.
-
(2013)
Leuk Lymphoma.
, vol.54
, Issue.8
, pp. 1823-1825
-
-
Davids, M.S.1
Letai, A.2
Brown, J.R.3
-
35
-
-
84977272170
-
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
-
COI: 1:CAS:528:DC%2BC28Xhs12ktbvF, PID: 27095788
-
Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127(25):3192–201.
-
(2016)
Blood.
, vol.127
, Issue.25
, pp. 3192-3201
-
-
Bojarczuk, K.1
Sasi, B.K.2
Gobessi, S.3
Innocenti, I.4
Pozzato, G.5
Laurenti, L.6
-
36
-
-
84928734902
-
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
-
PID: 25797245
-
Chiron D, Dousset C, Brosseau C, Touzeau C, Maiga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6(11):8750–9.
-
(2015)
Oncotarget.
, vol.6
, Issue.11
, pp. 8750-8759
-
-
Chiron, D.1
Dousset, C.2
Brosseau, C.3
Touzeau, C.4
Maiga, S.5
Moreau, P.6
-
37
-
-
84903650423
-
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
-
COI: 1:CAS:528:DC%2BC2cXhtFegu7bF, PID: 24829205
-
Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123(26):4132–5.
-
(2014)
Blood.
, vol.123
, Issue.26
, pp. 4132-4135
-
-
Wodarz, D.1
Garg, N.2
Komarova, N.L.3
Benjamini, O.4
Keating, M.J.5
Wierda, W.G.6
-
38
-
-
84907200622
-
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician
-
COI: 1:CAS:528:DC%2BC2cXitVClt7%2FE, PID: 25049322
-
Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32(27):3039–47.
-
(2014)
J Clin Oncol.
, vol.32
, Issue.27
, pp. 3039-3047
-
-
Byrd, J.C.1
Jones, J.J.2
Woyach, J.A.3
Johnson, A.J.4
Flynn, J.M.5
-
39
-
-
84928253067
-
Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment
-
COI: 1:CAS:528:DC%2BC2MXntFSnsrc%3D, PID: 25908509
-
Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–60.
-
(2015)
Am J Hematol.
, vol.90
, Issue.5
, pp. 446-460
-
-
Hallek, M.1
-
40
-
-
84927732048
-
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
-
COI: 1:CAS:528:DC%2BC2MXotV2hs7c%3D, PID: 25700432
-
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.
-
(2015)
Blood.
, vol.125
, Issue.16
, pp. 2497-2506
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Burger, J.A.4
Blum, K.A.5
Coleman, M.6
-
41
-
-
84926178507
-
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
-
COI: 1:CAS:528:DC%2BC2MXmtV2mtb8%3D, PID: 25573991
-
Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7.
-
(2015)
Blood.
, vol.125
, Issue.13
, pp. 2062-2067
-
-
Jain, P.1
Keating, M.2
Wierda, W.3
Estrov, Z.4
Ferrajoli, A.5
Jain, N.6
|